The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 American Academy of Dermatology (AAD) annual meeting in Orlando, Florida. Shares of Biocon Ltd ended at ₹333.45, up by ₹0.35, or 0.11%, on the BSE.
